PHATHOM PHARMACEUTICALS INC (PHAT) Stock Price, Quote, News and Overview
NASDAQ:PHAT - Nasdaq - US71722W1071 - Common Stock - Currency: USD
PHAT Quote, Performance and Key Statistics
3.15
+0.01 (+0.32%)
The current stock price of PHAT is 3.15 USD. In the past month the price decreased by -35.45%. In the past year, price decreased by -70.11%.
PHAT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 54.91 | 716.27B | ||
| JNJ | JOHNSON & JOHNSON | 15.34 | 370.87B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.47 | 300.70B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.11 | 215.19B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.53 | 213.77B | ||
| MRK | MERCK & CO. INC. | 10.32 | 202.39B | ||
| PFE | PFIZER INC | 7.19 | 130.95B | ||
| SNY | SANOFI-ADR | 13.4 | 125.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.56 | 98.05B | ||
| GSK | GSK PLC-SPON ADR | 6.86 | 75.61B | ||
| ZTS | ZOETIS INC | 26.9 | 72.23B | ||
| HLN | HALEON PLC-ADR | 22.31 | 48.29B |
Related stock screener links
About PHAT
Company Profile
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 427 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Company Info
PHATHOM PHARMACEUTICALS INC
100 Campus Drive, Suite 102
Florham Park NEW JERSEY 07932 US
CEO: Terrie Curran
Employees: 427
Phone: 18777428466
PHATHOM PHARMACEUTICALS INC / PHAT FAQ
What is the stock price of PHATHOM PHARMACEUTICALS INC today?
The current stock price of PHAT is 3.15 USD. The price increased by 0.32% in the last trading session.
What is the ticker symbol for PHATHOM PHARMACEUTICALS INC stock?
The exchange symbol of PHATHOM PHARMACEUTICALS INC is PHAT and it is listed on the Nasdaq exchange.
On which exchange is PHAT stock listed?
PHAT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PHATHOM PHARMACEUTICALS INC stock?
15 analysts have analysed PHAT and the average price target is 18.61 USD. This implies a price increase of 490.95% is expected in the next year compared to the current price of 3.15. Check the PHATHOM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PHATHOM PHARMACEUTICALS INC worth?
PHATHOM PHARMACEUTICALS INC (PHAT) has a market capitalization of 219.40M USD. This makes PHAT a Micro Cap stock.
How many employees does PHATHOM PHARMACEUTICALS INC have?
PHATHOM PHARMACEUTICALS INC (PHAT) currently has 427 employees.
What are the support and resistance levels for PHATHOM PHARMACEUTICALS INC (PHAT) stock?
PHATHOM PHARMACEUTICALS INC (PHAT) has a resistance level at 3.16. Check the full technical report for a detailed analysis of PHAT support and resistance levels.
Is PHATHOM PHARMACEUTICALS INC (PHAT) expected to grow?
The Revenue of PHATHOM PHARMACEUTICALS INC (PHAT) is expected to grow by 213.79% in the next year. Check the estimates tab for more information on the PHAT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PHATHOM PHARMACEUTICALS INC (PHAT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PHAT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PHAT, evaluating the profitability, health, valuation and growth aspects
- PHATHOM PHARMACEUTICALS INC (PHAT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PHATHOM PHARMACEUTICALS INC (PHAT) Sales and EPS estimates to see what analysts future expectations are.
- PHATHOM PHARMACEUTICALS INC (PHAT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PHATHOM PHARMACEUTICALS INC (PHAT) Insider and Institutional Ownership to learn about the owners and their transactions.
- PHATHOM PHARMACEUTICALS INC (PHAT) Stock Chart to make your own analysis
- PHATHOM PHARMACEUTICALS INC (PHAT) Latest news and press-releases to stay up to date.
Does PHATHOM PHARMACEUTICALS INC (PHAT) stock pay dividends?
PHAT does not pay a dividend.
When does PHATHOM PHARMACEUTICALS INC (PHAT) report earnings?
PHATHOM PHARMACEUTICALS INC (PHAT) will report earnings on 2025-08-06, before the market open.
What is the Price/Earnings (PE) ratio of PHATHOM PHARMACEUTICALS INC (PHAT)?
PHATHOM PHARMACEUTICALS INC (PHAT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5).
What is the Short Interest ratio of PHATHOM PHARMACEUTICALS INC (PHAT) stock?
The outstanding short interest for PHATHOM PHARMACEUTICALS INC (PHAT) is 20.17% of its float. Check the ownership tab for more information on the PHAT short interest.
PHAT Technical Analysis
PHAT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHAT. PHAT may be in some trouble as it scores bad on both profitability and health.
PHAT Financial Highlights
Over the last trailing twelve months PHAT reported a non-GAAP Earnings per Share(EPS) of -5. The EPS decreased by -13.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.53% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PHAT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to PHAT. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of 19% and a revenue growth 213.79% for PHAT